TAK-928

TAK-928 is a bispecific antibody developed by Takeda. Its targets are PD-1 and CD25 (IL-2 receptor alpha) (the sponsor names PD-1 x IL-2 receptor (CD25)). The sponsor states: Described as a first-in-class bispecific monoclonal antibody comprised of an IL-2 mutein fused with a recombinant anti-PD-1 antibody, intended to simultaneously block PD-(L)1 signalling and deliver IL-2 stimulation to tumour-specific CD8+ T cells co-expressing PD-1 and CD25, to reverse T-cell exhaustion. ClinicalTrials.gov describes the intervention as: TAK-928 will be administered by IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07217301 (A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07217301, plans to enrol 600 participants with primary completion expected 2028-11-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.